Urine concentrations of cysteinyl leukotrienes in children with obstructive sleep-disordered breathing

Athanasios G Kaditis1, Emmanouel Alexopoulos1, Konstantinos Chaidas1

  • 1Sleep Disorders Laboratory, University of Thessaly School of Medicine and Larissa University Hospital, Larissa, Greece.

Chest
|January 15, 2009
PubMed

Insights

Elevated urine cysteinyl leukotrienes (CysLTs) correlate with obstructive sleep apnea severity in children. This suggests CysLTs play a role in childhood sleep apnea development.

Area of Science:

  • Pediatric Pulmonology
  • Sleep Medicine
  • Biochemistry

Background:

  • Obstructive sleep-disordered breathing (SDB) in children is linked to increased cysteinyl leukotrienes (CysLTs) in adenotonsillar tissue.
  • Elevated CysLTs concentrations are also found in the exhaled breath of children with sleep apnea.

Purpose of the Study:

  • To examine the association between urine CysLTs levels and the severity of SDB in pediatric patients.
  • Investigate potential biomarkers for SDB severity in children.

Main Methods:

  • Urine CysLTs concentrations were measured in children with SDB symptoms and controls.
  • Polysomnography was used to assess SDB severity (obstructive apnea-hypopnea index [OAHI]).
  • Urine creatinine levels were used for normalization.

Main Results:

  • Children with moderate-to-severe SDB exhibited significantly higher urine CysLTs levels compared to those with mild SDB, primary snoring, or controls.
  • Log-transformed CysLTs concentration, tonsillar size, and BMI z-score were significant predictors of OAHI.
  • The study included groups with moderate-to-severe SDB, mild SDB, primary snoring, and healthy controls.

Conclusions:

  • Urine CysLTs excretion is directly related to the severity of obstructive sleep-disordered breathing in children.
  • These findings suggest that 5-lipoxygenase pathway products may contribute to the pathogenesis of childhood obstructive sleep apnea.
  • Alternatively, SDB itself might promote CysLTs biosynthesis.
Abstract

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...